about
Reappearance of minority K103N HIV-1 variants after interruption of ART initiated during primary HIV-1 infectionEarly antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruptionComplement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infectionVirus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors.Low human immunodeficiency virus envelope diversity correlates with low in vitro replication capacity and predicts spontaneous control of plasma viremia after treatment interruptions.Human immunodeficiency virus type 1 fitness is a determining factor in viral rebound and set point in chronic infection.Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5).A novel Acute Retroviral Syndrome Severity Score predicts the key surrogate markers for HIV-1 disease progression.Treatment-induced decline of human immunodeficiency virus-1 p24 and HIV-1 RNA in lymphoid tissue of patients with early human immunodeficiency virus-1 infectionGut commensal microbes do not represent a dominant antigenic source for continuous CD4+ T-cell activation during HIV-1 infection.In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10.HIV-1 replication activates CD4+ T cells with specificities for persistent herpes virusesIn vivo efficacy of human immunodeficiency virus neutralizing antibodies: estimates for protective titers.Potent human immunodeficiency virus-neutralizing and complement lysis activities of antibodies are not obligatorily linkedSimplified sample processing combined with a sensitive one-tube nested PCR assay for detection of Pneumocystis carinii in respiratory specimens.Monocyte-derived macrophages exhibit distinct and more restricted HIV-1 integration site repertoire than CD4(+) T cells.HIV rebounds from latently infected cells, rather than from continuing low-level replicationTracing HIV-1 transmission: envelope traits of HIV-1 transmitter and recipient pairsAssociation between specific HIV-1 Env traits and virologic control in vivo.Covalent attachment of hybridizable oligonucleotides to glass supports.Characterization of human immunodeficiency virus type 1 (HIV-1) diversity and tropism in 145 patients with primary HIV-1 infection.HIV sensitivity to neutralization is determined by target and virus producer cell properties.Determinants of HIV-1 broadly neutralizing antibody induction.Residual cell-associated unspliced HIV-1 RNA in peripheral blood of patients on potent antiretroviral therapy represents intracellular transcripts.PCR-derived ssDNA probes for fluorescent in situ hybridization to HIV-1 RNA.CD8+ T cells are activated in an antigen-independent manner in HIV-infected individuals.Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infection.Efficient suppression of minority drug-resistant HIV type 1 (HIV-1) variants present at primary HIV-1 infection by ritonavir-boosted protease inhibitor-containing antiretroviral therapy.Reliable one-tube nested PCR for detection and SSCP-typing of Pneumocystis carinii.Quantification of infectious HIV-1 plasma viral load using a boosted in vitro infection protocol.HIV-1 transmission after cessation of early antiretroviral therapy among men having sex with men.Humoral immunity to HIV-1: kinetics of antibody responses in chronic infection reflects capacity of immune system to improve viral set point.HIV-1 superinfection in an HIV-2-infected woman with subsequent control of HIV-1 plasma viremia.Positive in vivo selection of the HIV-1 envelope protein gp120 occurs at surface-exposed regions.Pulmonary Toxoplasmosis, a Rare but Severe Manifestation of a Common Opportunistic Infection in Late HIV Presenters: Report of Two CasesDelay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodiesImpact of TNFα, LTα, FcγRII and complement receptor on HIV-1 trapping in lymphoid tissue from HIV-infected patientsMolecular evidence of interhuman transmission in an outbreak ofPneumocystis jiroveciipneumonia among renal transplant recipientsPulmonary and intestinal microsporidiosis in a patient with the acquired immunodeficiency syndromeA method for the quantification of intracellular zidovudine nucleotides
P50
Q28478934-610AA23C-FD7B-4CBD-99B7-CAD5B8A4F2E9Q28742727-8F1BC453-D00B-442E-9ADA-C5102B12E200Q28766705-98541BE9-7DC2-422B-938D-7607B63B8612Q33843345-1A2831F5-78C4-4126-A114-8F6653AABD8BQ33883813-A0FEAB51-9C34-48C4-A5CB-D1562A12EB6EQ34227596-0CD76574-FAE1-4CE3-8FAC-C9AE480880ADQ34648499-4BFC5AC9-0E20-4BEA-BD6E-F00A84ED6A7CQ34662516-DE31C58A-B1E4-4FF1-A3AE-CB4E8FBED9B1Q35745547-0E270025-2F1F-483F-8FA1-ED0E198BCB0BQ35765806-B2860BAF-E398-4CC9-8785-FC8978835D02Q35947769-2DF0C0A4-02BC-4C37-9494-1F0FF84EF022Q36039280-10FF6BA4-D636-47FB-A160-58AA226CD66FQ36424125-6672887F-D285-4294-BC0A-D47CD52B3ED5Q36540060-9765E5CB-7EDD-4043-B749-3C2E80691449Q36544969-8C3A9C75-222C-42F7-94FD-537CE75F0F09Q36790007-47155561-C21B-4012-BDA0-C6889C0355B9Q36954950-D9CA6A09-5A04-4454-8CB4-75355925D3A0Q37233074-9A7B6963-74E5-44A3-AD1E-4225F71B44B7Q37570117-529C4C60-29C9-4440-A2CA-E9F2E57512E0Q38346906-3AFAD650-2E7E-4C1C-972B-BE77CA531FDDQ39398170-DE6F7D50-265E-426E-BAC7-F19738A5559AQ39828346-DA11906A-C4EC-40AD-8E51-E325A3745ED2Q40476608-0DCE99B0-FD2B-440B-B7A3-1FE4D0E2EA03Q40706493-3D03E9E0-1147-4179-BD89-608AA7B2E32AQ40905496-8C1088DF-15D5-458E-9FDE-78665386F9ABQ42242179-75B12F9F-48C2-4281-A5E4-C68DE8E72982Q42255433-A458CA6D-02B1-4009-B9EC-111605145125Q43145005-EC3A5409-9C5F-4C88-AA4D-0C0A18D3CA9BQ43504213-8B0C3498-8D22-45A8-8FFB-7F587826E855Q44985458-1BF4F689-369C-4744-A555-98737842B965Q46107497-7C698F11-AE01-422C-B249-3A5EC3E398A2Q47371942-0953C4E7-DBEE-46B3-B5B5-34E4DDBCAF80Q47971293-6CEE9A6E-0B4A-4871-9932-DEB368BB3294Q48078795-1BD37403-FD08-4803-90DD-4E0DF806921BQ57226268-0ED012A9-878C-42A9-A4AE-9E10878D10A3Q57226425-816DE055-C097-40C4-A21E-2D825B97965AQ57226554-1609B2FC-B235-4FAE-910A-18759AC92D2BQ61681924-21388D48-D195-451F-B495-6D06E967A75AQ67597388-70A413D0-C311-4A9E-A1B1-38DFBA37AD67Q67977106-8A450DA0-CCAC-4EDC-9742-37DBBD4688BE
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Herbert Kuster
@ast
Herbert Kuster
@en
Herbert Kuster
@es
Herbert Kuster
@nl
Herbert Kuster
@sl
type
label
Herbert Kuster
@ast
Herbert Kuster
@en
Herbert Kuster
@es
Herbert Kuster
@nl
Herbert Kuster
@sl
prefLabel
Herbert Kuster
@ast
Herbert Kuster
@en
Herbert Kuster
@es
Herbert Kuster
@nl
Herbert Kuster
@sl
P106
P21
P31
P496
0000-0001-6873-0091